img-left_technologyOverview2.jpg

Technology Overview

Akrivis’ patent-protected technology platform was named “Z-TECT™” for its ability to “D-TECT" molecules at the Zeptomole level.  “Zepto” is the prefix (abbreviated “z”) in the International System of Units denoting a factor of 10E–21 (following “atto (a)” for 10E–18, “femto (f)” for 10E–15, “pico (p)” for 10E–12 and “nano (n)” for 10E–9).

In contrast with the current sensitivity-limited immunoassays, Z-TECT™ is a unique technology platform that has been shown to detect analytes from various sample types down to the zeptomole range (10E–21 moles).  Achieving detection down to the femtogram/ml (fg/ml) range represents a 10-1,000 fold improvement in sensitivity over the best ELISA (Enzyme–Linked Immuno Sorbent Assay) immunoassays, which are typically limited to the picogram/ml (pg/ml) range.

In its essence, Akrivis’ Z-TECT™ payload amplification technology platform is composed of two units: a Z-TECT™ Targeting Unit (ZTU) and a Z-TECT™ Carrier Unit (ZCU).

The ZTU is derived from a chosen targeting agent, whether whole antibody, antibody fragment, antibody mimetic, protein, peptide or any other targeting agent.

The ZCU is based on a nanocarrier conjugated to a payload of molecules that generate a chosen signal, whether enzymes (e.g. HRP, ALP, etc), fluorophores (including NIR dyes), radioisotopes (e.g. 99mTc, 111In, 89Zr, 64Cu, 68Ga, etc) or any other signaling molecules.

One of the unique features of the
Z-TECT™ technology platform is that these ZTU and ZCU units are “bio-orthogonal”, meaning that they form high affinity/high specificity complexes with each other and only with each other.  In addition, since the entire system is specially designed to maintain low background levels, the resulting signal-to-noise ratio is increased and better quantitative accuracy can be achieved.

Z-TECT™ In Vitro Detection:  ZTU and ZCU are used as a single reagent while still offering the platform’s modularity benefit of “mixing and matching” different ZTUs (i.e. different targeting agents) with different ZCUs (i.e. different signal types).  In this configuration, Akrivis’ Z-TECT™ technology platform can achieve, in well-designed assays (i.e. with optimal antibody affinity/specificity characteristics and well-matched capture/detection antibodies), the detection of molecules down to the femtogram/ml range (1 fg/ml = 0.001 pg/ml).

Z-TECT™ In Vivo Imaging:  ZTU and ZCU are separately injected i.v. for use in animal models, providing the platform with its high resolution and high contrast imaging.  In this configuration, Akrivis’ Z-TECT™ technology platform can achieve the high resolution/high contrast imaging of mm-sized tumors or xenografts with various imaging modalities (optical or nuclear imaging such as gamma imaging, MRI, PET, SPECT, etc

For more information about Akrivis’ Z-TECT™ technology platform, please contact us at info@akrivis.com.